Pharmaphylogeny vs. pharmacophylogenomics: molecular phylogeny, evolution and drug discovery.
- Author:
Da-cheng HAO
1
;
Pei-gen XIAO
;
Ming LIU
;
Yong PENG
;
Chun-nian HE
Author Information
1. Dalian Jiatong University, China. hao@djtu.edu.cn
- Publication Type:Journal Article
- MeSH:
Drug Discovery;
Pharmacogenetics;
Phylogeny;
Plants, Medicinal;
chemistry;
genetics
- From:
Acta Pharmaceutica Sinica
2014;49(10):1387-1394
- CountryChina
- Language:Chinese
-
Abstract:
With the surge of high-throughput sequencing technology, it is becoming popular to perform the phylogenetic study based on genomic data. A bundle of new terms is emerging, such as phylogenomics, pharmacophylogenomics and phylotranscriptomics, which are somewhat overlapping with pharmaphylogeny. Phylogenomics is the crossing of evolutionary biology and genomics, in which genome data are utilized for evolutionary reconstructions. Pharmaphylogeny, advocated by Prof. Pei-gen Xiao since 1980s, focuses on the phylogenetic relationship of medicinal plants and is thus nurtured by molecular phylogeny, chemotaxonomy and bioactivity studies. Phylogenomics can be integrated into the flow chart of drug discovery and development, and extend the field of pharmaphylogeny at the omic level, thus the concept of pharmacophylogenomics could be redefined. This review gives a brief analysis of the association and the distinguished feature of the pharmaphylogeny related terms, in the context of plant-based drug discovery and sustainable utilization of pharmaceutical resource.
